Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Belimumab Treatment for IgG4-related Disease

during the treatment. Belimumab is an IgG1-lambda monoclonal antibody that prevents the survival of B lymphocytes by blocking the binding of soluble human B lymphocyte stimulator protein (BLyS) to

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Phase 1 Evaluation of the Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

infections. Low levels of CD4 cells may make a person more likely to get sick. There are no approved treatments for ICL. Researchers think a drug called belimumab may be able to help in specific situations

  • 109 views
  • 21 Sep, 2022
  • 1 location
Synergetic B-cell Immunomodulation in SLE - 2nd Study. (SynBioSe-2)

-cell targeting by starting treatment with belimumab (anti-BAFF) followed by rituximab(anti-CD20) in lupus nephritis patients.

myositis
elisa
baff
mycophenolate
azathioprine
  • 28 views
  • 27 Apr, 2022
  • 4 locations
BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with relapsed and/or refractory SLE.

  • 0 views
  • 09 Aug, 2022
  • 1 location
Trial of Belimumab in Early Lupus

This two year study will evaluate the effects of giving belimumab (Benlysta) to patients with Early Lupus. Early lupus is a diagnosis of lupus within 2 years. Subjects will be randomized to

ds dna
corticosteroids
hydroxychloroquine
belimumab
benlysta
  • 0 views
  • 12 Dec, 2021
  • 1 location
The BeLimumab Antiphospholipid Syndrome Trial (BLAST) (BLAST)

AIM: The primary objective of the BeLimumab Antiphospholipid Syndrome Trial (BLAST) is to evaluate the safety and tolerability of belimumab for up to 24 months in patients with persistent aPL

anticardiolipin antibody
warfarin
heparin
anticoagulant
lupus
  • 40 views
  • 05 Jun, 2022
  • 1 location
Belimumab With Rituximab for Primary Membranous Nephropathy

The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete remission (CR) compared to rituximab alone in

monoclonal antibodies
remission
nephrotic syndrome
lupus
proteinuria
  • 340 views
  • 12 Sep, 2021
  • 11 locations
Belimumab in Patients With Chronic Lymphocytic Leukemia (BeliVeR)

This study is a phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemia (CLL). Treatment of CLL has drastically

  • 0 views
  • 25 Mar, 2022
Efficacy and Safety of Belimumab in SLE Patients

problems. Belimumab is the only FDA-approved biological agent for SLE. Data showed that treatment with belimumab on the background of standard therapy was effective in active SLE patients. However, the

mycophenolate
azathioprine
lupus
autoimmune disease
tacrolimus
  • 0 views
  • 14 Jun, 2022
  • 1 location
Rituximab and Belimumab Combination Therapy in PR3 Vasculitis (COMBIVAS)

Mechanistic study to assess whether dual B-cell immunotherapy by co-administration of rituximab and belimumab will result in improvements in biological endpoints, functional outcomes and

microscopic polyangiitis
anca
prednisolone
rituximab
belimumab
  • 19 views
  • 09 Feb, 2022
  • 1 location